89849-80-9

Upstream product

• 14399-53-2 bis(iodomethyl)zinc 
• 74141-12-1 (Z)-3-(tributylstannanyl)prop-2-en-1-ol 
• 161344-84-9 (4S,5S)-2-butyl-N⁴,N⁴,N⁵,N⁵-tetramethyl-1,3,2-dioxaborolane-4,5-dicarboxamide 
• 82994-41-0 (E)-3-(tri-n-butylstannyl)-2-propen-1-ol 
• 75-11-6 diiodomethane 
• 688-73-3 tri-n-butyl-tin hydride 

Downstream Products

• 221016-23-5 (1S,2R)-2-(hydroxymethyl)-1-(2,3,5,6-tetramethylphenylthio)cyclopropane 
• 832132-85-1 (1R,2S)-2-(tributylstannyl)cyclopropanecarbaldehyde 

Relevant academic research and scientific papers

Enantioselective cyclopropanation of allylic alcohols with dioxaborolane ligands: Scope and synthetic applications

A very effective chiral controller has been found for the conversion of allylic alcohols into the corresponding enantiomerically enriched cyclopropanes using bis(iodomethyl)zinc. A variety of chiral, nonracemic cyclopropylmethanols could be obtained according to this method. This methodology was extended with success to the cyclopropanation of unconjugated and conjugated polyenes and homoallylic alcohols. The cyclopropanation of allylic carbamates has also been investigated with this system, but it was found that enantioenriched cyclopropylmethylamines are best prepared from enantioenriched cyclopropylmethanols.

SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula I wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES

The present invention relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular a

THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

The present invention relates to thiazole derivatives of Formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cere

SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula (I) wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES

The present invention relates to 2-phenyl-4-cyclopropyl-pyrimidine derivatives and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular a

PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

Synthesis of dictyopterene A: Optically active tributylstannylcyclopropane as a chiral synthon

Synthesis of (IS,2R)-1-[(E)-hex-1-en-1-yl]-2-vinylcyclopropane (dictyopterene A), which was isolated from the essential oil of algae of the genus Dictyopteris in Hawaii, has been demonstrated using optically active tributylstannylcyclopropane as a starting chiral synthon.